VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.

A descrição da empresa é mostrada em inglês.

Visitar site →

Estatísticas Principais

Capitalização: $263.02M
Índice P/L: N/A
Máx. 52 Sem.: $27.36
Mín. 52 Sem.: $1.70
Volume Médio: 415.37K

Dados fornecidos pelo Yahoo Finance via yfinance. Atualizado diariamente.

Informações da Empresa

Indústria: Biotecnologia
Bolsa: NASDAQ
País: Germany